Overview

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

There is no positive data on osimertinib in the treatment of metastatic EGFR mutation positive non-small-cell lung cancer (NSCLC). The purpose of this study is to study osimertinib combined with bevacizumab in the management of patients with brain metastasis harboring EGFR mutation.

Phase:

Phase 3

Details

Lead Sponsor:

Qingdao Central Hospital

Treatments:

Osimertinib